Bausch Health Companies (NYSE:BHC) Shares Down 5.8% - What's Next?

Bausch Health Companies Inc. (NYSE:BHC - Get Free Report)'s stock price fell 5.8% during mid-day trading on Monday . The company traded as low as $5.11 and last traded at $5.11. 1,075,501 shares traded hands during mid-day trading, a decline of 60% from the average session volume of 2,675,729 shares. The stock had previously closed at $5.42.

Analysts Set New Price Targets

A number of research firms have recently commented on BHC. Royal Bank of Canada upped their price objective on shares of Bausch Health Companies from $8.50 to $10.00 and gave the company a "sector perform" rating in a research note on Friday, May 2nd. StockNews.com downgraded Bausch Health Companies from a "buy" rating to a "hold" rating in a report on Saturday. Finally, Jefferies Financial Group reiterated a "hold" rating and issued a $8.00 target price (down previously from $12.00) on shares of Bausch Health Companies in a report on Thursday, February 6th. One research analyst has rated the stock with a sell rating and seven have given a hold rating to the stock. According to data from MarketBeat, Bausch Health Companies has an average rating of "Hold" and a consensus price target of $7.42.

Bausch Health Companies Trading Down 3.2 %

The stock has a market capitalization of $1.65 billion, a PE ratio of -37.91, a PEG ratio of 0.37 and a beta of 0.34. The business's 50-day moving average is $5.79 and its two-hundred day moving average is $7.10.

Bausch Health Companies (NYSE:BHC - Get Free Report) last issued its earnings results on Wednesday, February 19th. The company reported $1.21 earnings per share for the quarter, missing the consensus estimate of $1.65 by ($0.44). The company had revenue of $2.56 billion during the quarter, compared to analysts' expectations of $2.51 billion. Bausch Health Companies had a negative return on equity of 577.82% and a negative net margin of 0.48%. On average, analysts predict that Bausch Health Companies Inc. will post 4.41 EPS for the current year.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in the company. Tobam lifted its holdings in Bausch Health Companies by 10.4% in the 4th quarter. Tobam now owns 15,034 shares of the company's stock worth $121,000 after buying an additional 1,422 shares in the last quarter. Toronto Dominion Bank lifted its stake in shares of Bausch Health Companies by 1.0% in the fourth quarter. Toronto Dominion Bank now owns 167,212 shares of the company's stock worth $1,350,000 after acquiring an additional 1,712 shares in the last quarter. Wells Fargo & Company MN boosted its holdings in Bausch Health Companies by 7.9% in the fourth quarter. Wells Fargo & Company MN now owns 25,907 shares of the company's stock valued at $209,000 after purchasing an additional 1,896 shares during the last quarter. American Century Companies Inc. grew its stake in Bausch Health Companies by 10.6% during the 4th quarter. American Century Companies Inc. now owns 27,236 shares of the company's stock valued at $220,000 after purchasing an additional 2,600 shares in the last quarter. Finally, Blair William & Co. IL increased its holdings in Bausch Health Companies by 3.2% during the 4th quarter. Blair William & Co. IL now owns 84,707 shares of the company's stock worth $683,000 after purchasing an additional 2,622 shares during the last quarter. 78.65% of the stock is owned by institutional investors and hedge funds.

Bausch Health Companies Company Profile

Bausch Health Companies Inc operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health.